Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review
Descripción del Articulo
Objective: To describe the methods used to predict preeclampsia and how to preventit using low-dose acetylsalicylic acid (aspirin) according to the recommendationsof the main obstetrics and gynecology organizations. Methodology: We searchedPubMed and Cochrane Library from January 1, 2020, to May 1,...
| Autor: | |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2022 |
| Institución: | Sociedad Peruana de Obstetricia y Ginecología |
| Repositorio: | Revista Peruana de Ginecología y Obstetricia |
| Lenguaje: | español inglés |
| OAI Identifier: | oai:ginecologiayobstetricia.pe:article/2453 |
| Enlace del recurso: | https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453 |
| Nivel de acceso: | acceso abierto |
| Materia: | Preeclampsia prevención predicción Doppler Aspirina Pre-eclampsia prevention prediction Doppler effect Aspirin |
| id |
REVSPOG_496f1a7c558c0545e06e8ab719d3f6ae |
|---|---|
| oai_identifier_str |
oai:ginecologiayobstetricia.pe:article/2453 |
| network_acronym_str |
REVSPOG |
| network_name_str |
Revista Peruana de Ginecología y Obstetricia |
| repository_id_str |
. |
| dc.title.none.fl_str_mv |
Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review Evidencias del ácido acetilsalicílico (aspirina) en la prevención de la preeclampsia: revisión narrativa |
| title |
Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review |
| spellingShingle |
Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review Vigil-De Gracia, Paulino Preeclampsia prevención predicción Doppler Aspirina Pre-eclampsia prevention prediction Doppler effect Aspirin |
| title_short |
Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review |
| title_full |
Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review |
| title_fullStr |
Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review |
| title_full_unstemmed |
Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review |
| title_sort |
Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review |
| dc.creator.none.fl_str_mv |
Vigil-De Gracia, Paulino |
| author |
Vigil-De Gracia, Paulino |
| author_facet |
Vigil-De Gracia, Paulino |
| author_role |
author |
| dc.subject.none.fl_str_mv |
Preeclampsia prevención predicción Doppler Aspirina Pre-eclampsia prevention prediction Doppler effect Aspirin |
| topic |
Preeclampsia prevención predicción Doppler Aspirina Pre-eclampsia prevention prediction Doppler effect Aspirin |
| description |
Objective: To describe the methods used to predict preeclampsia and how to preventit using low-dose acetylsalicylic acid (aspirin) according to the recommendationsof the main obstetrics and gynecology organizations. Methodology: We searchedPubMed and Cochrane Library from January 1, 2020, to May 1, 2022, using theterms “pre-eclampsia”, “hypertensive disorders in pregnancy” and “hypertensionand pregnancy”. We focused on the analyses and recommendations from the mostrecognized international obstetrics and gynecology organizations, independent ofthe original language. Results: For the prediction of preeclampsia, two strategies areused that aim to find the population at highest risk based on: 1) clinical findingsof risk for pre-pregnancy or pregnancy conditions, and 2) a multi-factor algorithmthat includes clinical findings, blood pressure, biomarker and uterine artery Doppler.Using both strategies, variable effectiveness of aspirin in preventing preeclampsiais found. The most effective dose range between 50-150 mg, with 81 mg being themost recommended at present. The dose of 150 mg per day has shown effectivenessin preeclampsia far from term; however, it is considered to have more side effects.Conclusions: The most prestigious and recognized obstetrics and gynecologyand health organizations recommend low-dose aspirin to prevent preeclampsia,preferably at the beginning of the second trimester of pregnancy and maintaineduntil 36-37 weeks. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022-12-20 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453 10.31403/rpgo.v68i2453 |
| url |
https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453 |
| identifier_str_mv |
10.31403/rpgo.v68i2453 |
| dc.language.none.fl_str_mv |
spa eng |
| language |
spa eng |
| dc.relation.none.fl_str_mv |
https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453/2691 https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453/2692 |
| dc.rights.none.fl_str_mv |
Derechos de autor 2022 Paulino Vigil-De Gracia https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Derechos de autor 2022 Paulino Vigil-De Gracia https://creativecommons.org/licenses/by/4.0 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Sociedad Peruana de Obstetricia y Ginecología |
| publisher.none.fl_str_mv |
Sociedad Peruana de Obstetricia y Ginecología |
| dc.source.none.fl_str_mv |
The Peruvian Journal of Gynecology and Obstetrics ; Vol. 68 No. 4 (2022) Revista Peruana de Ginecología y Obstetricia; Vol. 68 Núm. 4 (2022) 2304-5132 2304-5124 reponame:Revista Peruana de Ginecología y Obstetricia instname:Sociedad Peruana de Obstetricia y Ginecología instacron:SPOG |
| instname_str |
Sociedad Peruana de Obstetricia y Ginecología |
| instacron_str |
SPOG |
| institution |
SPOG |
| reponame_str |
Revista Peruana de Ginecología y Obstetricia |
| collection |
Revista Peruana de Ginecología y Obstetricia |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1868078737103257600 |
| spelling |
Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative reviewEvidencias del ácido acetilsalicílico (aspirina) en la prevención de la preeclampsia: revisión narrativaVigil-De Gracia, PaulinoPreeclampsiaprevenciónpredicciónDopplerAspirinaPre-eclampsiapreventionpredictionDoppler effectAspirinObjective: To describe the methods used to predict preeclampsia and how to preventit using low-dose acetylsalicylic acid (aspirin) according to the recommendationsof the main obstetrics and gynecology organizations. Methodology: We searchedPubMed and Cochrane Library from January 1, 2020, to May 1, 2022, using theterms “pre-eclampsia”, “hypertensive disorders in pregnancy” and “hypertensionand pregnancy”. We focused on the analyses and recommendations from the mostrecognized international obstetrics and gynecology organizations, independent ofthe original language. Results: For the prediction of preeclampsia, two strategies areused that aim to find the population at highest risk based on: 1) clinical findingsof risk for pre-pregnancy or pregnancy conditions, and 2) a multi-factor algorithmthat includes clinical findings, blood pressure, biomarker and uterine artery Doppler.Using both strategies, variable effectiveness of aspirin in preventing preeclampsiais found. The most effective dose range between 50-150 mg, with 81 mg being themost recommended at present. The dose of 150 mg per day has shown effectivenessin preeclampsia far from term; however, it is considered to have more side effects.Conclusions: The most prestigious and recognized obstetrics and gynecologyand health organizations recommend low-dose aspirin to prevent preeclampsia,preferably at the beginning of the second trimester of pregnancy and maintaineduntil 36-37 weeks.Objetivo. Describir los métodos usados para predecir preeclampsia y cómo prevenirla usando ácido acetilsalicílico (aspirina) a dosis bajas de acuerdo con las recomendaciones de las principales organizaciones de ginecología y obstetricia. Metodología. Se realizaron búsquedas en PubMed y Cochrane Library desde el 1 de enero de 2020 al 1 de mayo de 2022, con los términos “pre-eclampsia”, “trastornos hipertensivos en el embarazo” e “hipertensión y embarazo”. Nos enfocamos en los análisis y recomendaciones de las más reconocidas organizaciones internacionales de ginecología y obstetricia, independiente del idioma original. Resultados. Para la predicción de preeclampsia se usan dos estrategias que pretenden encontrar la población con más riesgo: 1) basada en hallazgos clínicos de riesgo por condiciones antes del embarazo o propias del embarazo, y 2) un algoritmo de múltiples factores que incluye hallazgos clínicos, presión arterial, biomarcador y Doppler de arteria uterina. Usando ambas estrategias se muestra efectividad variable de la aspirina en prevenir la preeclampsia. Se considera las dosis más efectivas entre 50 y 150 mg, siendo 81 mg la más recomendada en la actualidad. La dosis de 150 mg por día ha mostrado efectividad en la preeclampsia lejos del término; sin embargo, se considera que tiene más efectos secundarios. Conclusiones. Las más prestigiosas y reconocidas organizaciones de ginecología y obstetricia y de salud recomiendan aspirina a dosis bajas para prevenir la preeclampsia, preferiblemente al iniciar el segundo trimestre de gestación y mantenerla hasta las 36 a 37 semanas.Sociedad Peruana de Obstetricia y Ginecología2022-12-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://ginecologiayobstetricia.pe/index.php/RPGO/article/view/245310.31403/rpgo.v68i2453The Peruvian Journal of Gynecology and Obstetrics ; Vol. 68 No. 4 (2022)Revista Peruana de Ginecología y Obstetricia; Vol. 68 Núm. 4 (2022)2304-51322304-5124reponame:Revista Peruana de Ginecología y Obstetriciainstname:Sociedad Peruana de Obstetricia y Ginecologíainstacron:SPOGspaenghttps://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453/2691https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453/2692Derechos de autor 2022 Paulino Vigil-De Graciahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:ginecologiayobstetricia.pe:article/24532026-01-12T15:21:29Z |
| score |
13.411838 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).